Study of the expression of oncoprotein p53, EGFR in colorectal carcinomas with different proliferative activity
DOI:
https://doi.org/10.26641/2307-0404.2023.1.275703Keywords:
colorectal carcinoma, digital morphometry, p53, EGFR, Ki-67Abstract
Colorectal cancer, according to the International Agency for Research on Cancer, was and remains an urgent problem worldwide. In 2020, in Ukraine, morphological verification of new cases of colon and rectal cancer was carried out at a high level (83.2% and 89.5%, respectively), but despite this, specific treatment covered only 69.4% and 74.5% of eligible patients, that is why about a third of patients (30.8% of colon cancer patients and 25.0% of rectal cancer patients) did not live even a year from the moment of its detection in 2020. The aim of the study was to evaluate the prognostic significance of the expression of p53 and EGFR markers depending on the clinical, morphological characteristics and proliferative activity of colorectal carcinomas. The clinical and anatomical material of 37 patients (15 women and 22 men) was studied in the work. The age of the patients ranged from 27 to 82 years; the average age was 61.43±14.90 years. Antibodies to Ki-67, p53, EGFR and the UltraVision Quanto visualization system (LabVision) were used for immunohistochemical research. Digital morphometry was performed in the Fiji platform with the calculation of percentages of p53 and Ki-67-positive intranuclear reactions with the ImmunoRatio plugin. The distribution of p53 expression variants - wild type (0<p53 <10%) or "mutant" (overexpression ≥10% or completely negative samples) showed no significant difference in any group (all p>0.05), despite that among men, mutant expression of p53 was significantly higher than among women – 72.72% (16 out of 22) versus 53.33% (8 out of 15), and all patients under the age of 50 years had a mutant type of p53 expression 9 out of 9 (100%), while the number of such observations after 50 years already decreased to about half – 15 out of 28 (53.57%). The distribution of EGFR expression variants showed a significant difference in subgroups according to grade (p<0.05) and in subgroups with different proliferative potential according to Ki-67 (p<0.05).
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Scientific Reports. 2020;71(3):209-49. doi: https://doi.org/10.3322/caac.21660
Heather NM, Ward A, Jenab M, et al. Hetero-geneity of Colorectal Cancer Risk Factors by Anatomical Subsite in 10 European Countries: A Multinational Cohort Study. Clinical Gastroenterology and Hepatology. 2019;17(7):1323-31.e6. doi: https://doi.org/10.1016/j.cgh.2018.07.030
Hofseth LJ, Hebert JR, Chanda A, et al. Early-onset colorectal cancer: initial clues and current views. Nature Reviews Gastroenterology & Hepatology. 2020;17:352-64. doi: https://doi.org/10.1038/s41575-019-0253-4
Graff RE, Möller S, Passarelli MN, et al. Familial Risk and Heritability of Colorectal Cancer in the Nordic Twin Study of Cancer. Clinical Gastroenterology and Hepatology. 2017;15(8):1256-64. doi: https://doi.org/10.1016/j.cgh.2016.12.041
Fedorenko ZP, Hulak LO, Mykhailovych YuY, et al. [Cancer in Ukraine, 2019-2020. Morbidity, mortality, performance indicators of the oncology service]. Bulletin of the National Chancery Register of Ukraine. [Internet]. 2021 [cited 2022 Nov 20];22. Ukrainian. Available from: http://www.ncru.inf.ua/publications/BULL_22/
Zhang Q, Wu J, Bai X, Liang T. Evaluation of Intra-Tumoral Vascularization in Hepatocellular Carcinomas. Front Med. 2020;7:584250. doi: https://doi.org/10.3389/fmed.2020.584250
Melling N, Kowitz CM, Simon R, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69:209-14. doi: https://doi:10.1136/jclinpath-2015-202985
Poslavska OV, Shponka IC, Hrytsenko PO. [Characteristics of the colorectal phenotype of carcinomas of unknown primary localization]. Actual problems of pediatric medicine. 2018;18(3):111-5. Ukrainian.
Luo Z-W, Zhu M-G, Zhang Z-Q, et al. Increased expression of Ki-67 is a poor prognostic marker for colorectal cancer patients: a meta analysis. BMC Cancer. 2019;19(123):1-13. doi: https://doi.org/10.1186/s12885-019-5324-y
Nakayama M, Oshima M. Mutant p53 in colon cancer. Journal of Molecular Cell Biology. 2019;11(4):267-76. doi: https://doi.org/10.1093/jmcb/mjy075
Solé L, Lobo-Jarne T, Álvarez-Villanueva D, et al. p53 wild-type colorectal cancer cells that express a fetal gene signature are associated with metastasis and poor prognosis. Nat Commun. 2022;13(2866):1-15. doi: https://doi.org/10.1038/s41467-022-30382-9
Li X-L, Zhou J, Chen Z-R, Chng W-J. p53 muta-tions in colorectal cancer - molecular pathogenesis and pharmacological reactivation. World J Gastroenterol. 2015;21(1):84-93. doi: https://doi.org/10.3748/wjg.v21.i1.84
Lieb MC, Hofmann TG. The Role of p53 Signaling in Colorectal Cancer. Cancers (Basel). 2021;13(9):2125. doi: https://doi.org/10.3390/cancers13092125
Nigro CL, Ricci V, Vivenza D, et al. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy. World J Gastroenterol. 2016;22(30):6944-54. doi: https://doi.org/10.3748/wjg.v22.i30.6944
Martinelli E, Ciardiello D, Martini G. Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives. Annals of Oncology. 2020;31(1):30-40. doi: https://doi.org/10.1016/j.annonc.2019.10.007
Balakarthikeyan J, Mayakrishnan V, Kannap-pan P, et al. EGFR-Based Targeted Therapy for Colorectal Cancer – Promises and Challenges. Vaccines (Basel). 2022;10(4):499. doi: https://doi.org/10.3390/vaccines10040499
Li Q-H, Wang Y-Z, Tu J, et al. Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance. Gastroenterology Report. 2020;8(3):179-91. doi: https://doi.org/10.1093/gastro/goaa026
Vareniuk IM, Dzerzhynskyi ME. [Methods of cyto-histological diagnosis: study guide]. Kyiv; 2019. 256 p. Ukrainian.
Nguyen T. Immunohistochemistry: A Technical Guide to Current Practices. Cambridge: Cambridge University Press; 2022. 272 p.
Poslavska OV. [The methodology of using soft-ware for the analysis of digital photomicrographs based on the course of pathomorphology in order to improve the professional level of students and scientists]. Morphologia. 2015;9(3):122-6. Ukrainian.
Poslavska OV. [Determining the linear dimensions and areas of individual morphological objects on photomicrographs using the ImageJ program]. Morphologia. 2016;10(3):377-81. Ukrainian. doi: https://doi.org/10.26641/1997-9665.2016.3.377-381
Strahova OP, Androsov OI. [Statistical methods of processing the results of medical and biological research]. Lviv; 2021. 164 p. Ukrainian.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medicni perspektivi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
